Alnylam Pharmace. buy Bank of America Co.
Start price
25.06.24
/
50%
€222.50
Target price
25.06.25
€275.35
Performance (%)
24.90%
End price
26.06.25
€277.90
Summary
This prediction ended on 26.06.25 with a price of €277.90. The prediction had a final performance of 24.90%. Bank_of_America_Co_ has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. Bank_of_America_Co_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | 0.407% | 0.407% | 59.717% |
| iShares Core DAX® | 1.644% | 3.553% | 28.173% |
| iShares Nasdaq 100 | 2.211% | 6.941% | 18.364% |
| iShares Nikkei 225® | 3.718% | 6.703% | 11.335% |
| iShares S&P 500 | 1.557% | 5.211% | 12.019% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Bank of America Co. from $248.00 to $295.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von Bank_of_America_Co_ gewählte maximale Laufzeit wurde überschritten
Current prediction by Bank_of_America_Co_ for Alnylam Pharmace.
Stopped prediction by Bank_of_America_Co_ for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€228.50
04.09.24
04.09.24
€277.62
04.09.25
04.09.25
69.02%
05.09.25
05.09.25
